Lonnie D. Shea
University of Michigan
346 Papers
2.3K Citations
Lonnie D. Shea is an academic researcher from University of Michigan. The author has contributed to research in topics: Gene delivery & Ovarian follicle. The author has an hindex of 75, co-authored 320 publications. Previous affiliations of Lonnie D. Shea include Northwestern University & Georgia Institute of Technology.
Chat about Author
Papers
Fibrin-mediated delivery of an ovarian follicle pool in a mouse model of infertility.
Rachel M. Smith,Ariella Shikanov,Ekaterina Kniazeva,Deepa Ramadurai,Teresa K. Woodruff,Lonnie D. Shea +5 more
TL;DR: This biomaterial may provide a platform for follicle transplantation with a low risk of cancer contamination and for developing strategies that preserve fertility for women facing a cancer diagnosis.
Synergistic effect of eribulin and CDK inhibition for the treatment of triple negative breast cancer
Shreyas S. Rao,Jenna R. Stoehr,Danijela Dokic,Lei Wan,Joseph T. Decker,Kristine E. Konopka,Alexandra L. Thomas,Jia Wu,Virginia G. Kaklamani,Lonnie D. Shea,Lonnie D. Shea,Jacqueline S. Jeruss +11 more
TL;DR: The potential of this novel drug combination, CYC065 and eribulin, to suppress the growth of TNBC cells in vitro and in vivo is highlighted, warranting further clinical investigation.
Localized lentivirus delivery via peptide interactions.
TL;DR: The modification of hydrogels with affinity proteins or peptides to bind lentivirus can be a powerful strategy to enhance and localized transgene expression.
DNA delivery from hyaluronic acid-collagen hydrogels via a substrate-mediated approach.
TL;DR: A substrate-mediated approach was developed to deliver DNA from hyaluronic acid-collagen hydrogels by topographically patterning the hydrogel to pattern cell adhesion andTransgene expression mediated by immobilized, large diameter complexes was 3 to 7-fold greater than for small diameter complexes.
Overcoming challenges in treating autoimmuntity: Development of tolerogenic immune-modifying nanoparticles.
Ryan M. Pearson,Joseph R. Podojil,Lonnie D. Shea,Nicholas J. C. King,Stephen D. Miller,Daniel R. Getts +5 more
TL;DR: The evolution of biomaterial approaches from cell-based therapies to induce immune tolerance with a focus on the Tolerogenic Immune-Modifying nanoParticle (TIMP) platform, which can be designed to treat various autoimmune conditions and is currently in clinical trials testing its ability to reverse celiac disease.